Advances in treatment also cater to tumours with other specific mutations, such as BRAF V600E, which have shown benefits from targeted therapy with Dabrafenib plus Trametinib in patients with BRAF V600E-mutated biliary tract cancer in a Phase 2 ROAR study [44]. Here, BRAF is linked to biliary tract cancer.